TMEM256: A Potential Drug Target and Biomarker for Membrane Transmembrane Proteins

Target Name: TMEM256

NCBI ID: G254863

TMEM256

TMEM256: A Potential Drug Target and Biomarker for Membrane Transmembrane Proteins

Introduction

Membrane transmembrane proteins (TMEMs) are a diverse family of proteins that play a crucial role in various cellular processes, including signaling, cell adhesion, cell migration and cell proliferation. TMEMs are characterized by their ability to span the membrane and interact with both intrinsically and extrinsically derived signals. The protein encoded by the Transmembrane Protein 256 (TMEM256) is a good example of this family. TMEM256 is a 21-kDa protein that is expressed in Various tissues and cells, including brain, heart, kidney, and cancer cells. It is involved in several cellular processes, including cell signaling, neurotransmission, and cancer progression.

TMEM256: Structure and Function

The TMEM256 protein is composed of 116 amino acid residues and has a calculated molecular weight of 13.9 kDa. It has a transmembrane domain that is responsible for its unique structure and function. The transmembrane domain is made up of four conserved domains: an N-terminal alpha-helix, a central beta-sheet, a C-terminal alpha-helix, and a variable carboxylic acid (C-terminal) site.

The N-terminal domain is the first structural domain that is encountered in TMEM256. It is an alpha-helix that is responsible for the overall stability and stability of the protein. The central beta-sheet is the second structural domain that is encountered in TMEM256 . It is a parallel beta-sheet that is composed of three尾-strands and has a conserved amino acid pattern. The C-terminal domain is the last structural domain that is encountered in TMEM256. It is a variable carboxylic acid site that is responsible for the protein's unique acidity and its ability to interact with other molecules.

The TMEM256 protein functions as a receptor for various signaling molecules, including neurotransmitters and hormones. It is involved in several cellular processes, including neurotransmission, cell signaling, and cancer progression. TMEM256 is also involved in the regulation of cellular processes that are critical for the survival of the cell, including cell adhesion, migration, and the regulation of the cell cycle.

TMEM256 as a Drug Target

TMEM256 has been identified as a potential drug target due to its unique structure and function. The transmembrane domain of TMEM256 makes it a potential receptor for small molecules, including drugs that can modulate its activity. The C-terminal domain of TMEM256 is responsible for its acidity, which makes it a potential receptor for acids that can modulate its activity.

TMEM256 has been shown to interact with several small molecules, including neurotransmitters, hormones, and inhibitors of cell signaling pathways. These interactions suggest that TMEM256 may be a useful target for drugs that can modulate its activity. For example, TMEM256 has been shown to interact with the neurotransmitter GABA, which is involved in several cellular processes, including neurotransmission and the regulation of the cell cycle.

TMEM256 has also been shown to interact with the hormone insulin, which is involved in glucose metabolism and cell signaling. The interaction between TMEM256 and insulin suggests that it may be a useful target for drugs that can modulate its activity.

TMEM256 as a Biomarker

TMEM256 has also been shown to be involved in the regulation of cellular processes that are critical for the survival of the cell. The transmembrane domain of TMEM256 is involved in the regulation of

Protein Name: Transmembrane Protein 256

The "TMEM256 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TMEM256 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets